Inactivated Rabies Virus-Vectored Immunocontraceptive Vaccine in a Thermo-Responsive Hydrogel Induces High and Persistent Antibodies against Rabies, but Insufficient Antibodies against Gonadotropin-Releasing Hormone for Contraception
Open Access
Abstract
Rabies is preventable through vaccination, but the need to mount annual canine vaccination campaigns presents major challenges in rabies control and prevention. The development of a rabies vaccine that ensures lifelong immunity and animal population management in one dose could be extremely advantageous. A nonsurgical alternative to spay/neuter is a high priority for animal welfare, but irreversible infertility in one dose has not been achieved. Towards this goal, we developed a rabies virus-vectored immunocontraceptive vaccine ERA-2GnRH, which protected against rabies virus challenge and induced >80% infertility in mice after three doses in a live, liquid-vaccine formulation (Wu et al., 2014). To improve safety and use, we formulated an inactivated vaccine in a thermo-responsive chitosan hydrogel for one-dose delivery and studied the immune responses in mice. The hydrogel did not cause any injection site reactions, and the killed ERA-2GnRH vaccine induced high and persistent rabies virus neutralizing antibodies (rVNA) in mice. The rVNA in the hydrogel group reached an average of 327.40 IU/mL, more than 200 times higher than the liquid vaccine alone. The Gonadotropin-releasing hormone (GnRH) antibodies were also present and lasted longer in the hydrogel group, but did not prevent fertility in mice, reflecting a possible threshold level of GnRH antibodies for contraception. In conclusion, the hydrogel facilitated a high and long-lasting immunity, and ERA-2GnRH is a promising dual vaccine candidate. Future studies will focus on rabies protection in target species and improving the anti-GnRH response.Keywords
This publication has 54 references indexed in Scilit:
- Host–rabies virus protein–protein interactions as druggable antiviral targetsProceedings of the National Academy of Sciences, 2013
- Evidence‐based control of canine rabies: a critical review of population density reductionJournal of Animal Ecology, 2012
- Antibody persistence, 32 years after post-exposure prophylaxis with human diploid cell rabies vaccine (HDCV)Vaccine, 2011
- Evaluation of Mass Vaccination Campaign Coverage Against Rabies in Dogs in TunisiaZoonoses and Public Health, 2011
- Development of combined vaccines for rabies and immunocontraceptionVaccine, 2009
- ORIGINAL ARTICLE: The Single‐Shot GnRH Immunocontraceptive Vaccine (GonaCon™) in White‐Tailed Deer: Comparison of Several GnRH PreparationsAmerican Journal of Reproductive Immunology, 2008
- Survival of neutralizing antibody in previously rabies vaccinated subjects: A prospective study showing long lasting immunityVaccine, 2006
- Long-Term Humoral and Cellular Immunity after Vaccination with Cell Culture Rabies Vaccines in ManClinical Immunology and Immunopathology, 1994
- Longevity of rabies antibody titre in recipients of human diploid cell rabies vaccineVaccine, 1992
- RabiesScientific American, 1980